DE14154918T1 - ADAM6 Mäuse - Google Patents

ADAM6 Mäuse Download PDF

Info

Publication number
DE14154918T1
DE14154918T1 DE14154918.8T DE14154918T DE14154918T1 DE 14154918 T1 DE14154918 T1 DE 14154918T1 DE 14154918 T DE14154918 T DE 14154918T DE 14154918 T1 DE14154918 T1 DE 14154918T1
Authority
DE
Germany
Prior art keywords
mouse
human
gene
gene segments
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE14154918.8T
Other languages
English (en)
Inventor
Sean Stevens
Andrew J. Murphy
Lynn Macdonald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45998616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE14154918(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of DE14154918T1 publication Critical patent/DE14154918T1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/22—Heating, cooling or ventilating [HVAC] devices the heat being derived otherwise than from the propulsion plant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/3228—Cooling devices using compression characterised by refrigerant circuit configurations
    • B60H1/32281—Cooling devices using compression characterised by refrigerant circuit configurations comprising a single secondary circuit, e.g. at evaporator or condenser side
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/323—Cooling devices using compression characterised by comprising auxiliary or multiple systems, e.g. plurality of evaporators, or by involving auxiliary cooling devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00642—Control systems or circuits; Control members or indication devices for heating, cooling or ventilating devices
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/00192—Distribution of conditionned air to left and right part of passenger compartment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/002—Distribution of conditionned air to front and rear part of passenger compartment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Abstract

Eine genetisch modifizierte Maus, deren Genom umfasst: (a) eine ektopische Nukleinsäuresequenz umfassend einer Sequenz, die ein Maus-Adam6a-Protein oder ein Ortholog oder Homolog oder Fragment davon kodiert, das in einer männlichen Maus funktionell ist, und ein Maus-Adam6b-Protein oder ein Ortholog oder Homolog oder Fragment davon kodiert, das in einer männlichen Maus funktionell ist; und (b) einen humanisierten Locus der variablen Region der schweren Immunglobulin-Kette.

Claims (19)

  1. Eine genetisch modifizierte Maus, deren Genom umfasst: (a) eine ektopische Nukleinsäuresequenz umfassend einer Sequenz, die ein Maus-Adam6a-Protein oder ein Ortholog oder Homolog oder Fragment davon kodiert, das in einer männlichen Maus funktionell ist, und ein Maus-Adam6b-Protein oder ein Ortholog oder Homolog oder Fragment davon kodiert, das in einer männlichen Maus funktionell ist; und (b) einen humanisierten Locus der variablen Region der schweren Immunglobulin-Kette.
  2. Die Maus vom Anspruch 1, wobei die ektopische Nukleinsäuresequenz am humanisierten Locus der variablen Region der schweren Immunglobulin-Kette vorliegt.
  3. Die Maus von Anspruch 2, wobei die ektopische Nukleinsäuresequenz innerhalb einer Sequenz der humanen schweren Kette des humanisierten Locus der variablen Region der schweren Kette liegt.
  4. Die Maus von Anspruch 1, wobei die ektopische Nukleinsäuresequenz an einer anderen Position als dem humanisierten Genlocus der variable-Region der schweren Kette vorhanden ist.
  5. Die Maus irgendeines der vorhergehenden Ansprüche, wobei der humanisierte Locus der variablen Region der schweren Immunglobulin-Kette eine Insertion eines oder mehrerer humanen/r VH-Gensegments/e, eines oder mehrerer humanen/r DH-Gensegments/e und eines oder mehrerer humanen/r JH-Gensegments/e umfasst.
  6. Maus von Anspruch 5, wobei der humanisierte Locus der variablen Region der schweren Immunglobulin-Kette umfasst: a) mindestens 18 humane VH-Gensegmente, 27 humane DH-Gensegmente und sechs humane JH-Gensegmente; b) mindestens 39 humane VH-Gensegmente, 27 humane DH-Gensegmente und sechs humane JH-Gensegmente; oder c) 80 humane VH-Gensegmente, 27 humane DH-Gensegmente und sechs humane JH-Gensegmente, wobei die humanen VH, DH und JH-Gensegmente funktionsfähig mit einem nicht-humanen Gen der konstanten Region verknüpft sind.
  7. Die Maus von Anspruch 6, wobei das nicht-humane Gen der konstanten Region ein Nagetier-Gen der konstanten Region ist.
  8. Die Maus von Anspruch 7, wobei das Nagetier-Gen der konstanten Region eine Maus-Gensequenz der konstanten Region umfasst, ausgewählt aus einer CH1, einer Gelenk, einer CH2, einer CH3, einer CH4 und eine Kombination davon.
  9. Die Maus irgendeines der vorhergehenden Ansprüche, weiter umfassend ein oder mehrere humane/s Vκ-Gensegment/e und ein oder mehrere humane/s Jκ-Gensegment/e.
  10. Die Maus von Anspruch 9, wobei das eine oder die mehreren humane/n Vκ-Gensegment/e und das eine oder die mehreren humane/n Jκ-Gensegment/e an einem endogenen Locus der leichten Immunglobulin-κ-Kette vorliegen.
  11. Die Maus von Anspruch 9 oder 10, wobei die Maus umfasst: a) mindestens 16 humane Vκ- und fünf humane Jκ-Gensegmente; b) mindestens 30 humane Vκ- und fünf humane Jκ-Gensegmente; oder c) mindestens 40 humane Vκ- und fünf humane Jκ-Gensegmente.
  12. Die Maus irgendeines der vorhergehenden Ansprüche, wobei der Maus endogene VH-, DH- und JH-Gensegmente fehlen.
  13. Die Maus irgendeines der vorhergehenden Ansprüche, wobei der Maus endogene Vκ-, und Jκ-Gensegmente fehlen.
  14. Eine isolierte Mauszelle, deren Genom umfasst: (a) eine ektopische Nukleinsäuresequenz, umfassend einer Sequenz, die ein Maus-Adam6a-Protein oder ein Ortholog oder Homolog oder Fragment davon kodiert, das in einer männlichen Maus funktionell ist, und ein Maus-Adam6b-Protein oder ein Ortholog oder Homolog oder Fragment davon kodiert, das in einer männlichen Maus funktionell ist; und b) ein humanisierter Locus der variablen Region der schweren Immunglobulin-Kette.
  15. Die isolierte Zelle gemäß Anspruch 14, wobei die Zelle eine B-Zelle ist.
  16. Ein Hybridom, das aus der B-Zelle von Anspruch 15 hergestellt wurde.
  17. Eine immortalisierte Zelle, die aus der isolierten Zelle von Anspruch 14 hergestellt wurde.
  18. Die isolierte Zelle gemäß Anspruch 14, wobei die Zelle eine embryonale Maus-Stammzelle ist.
  19. Ein Maus-Embryo, dessen Genom umfasst: (a) eine ektopische Nukleinsäuresequenz, umfassend einer Sequenz, die ein Maus-Adam6a-Protein oder ein Ortholog oder Homolog oder Fragment davon kodiert, das in einer männlichen Maus funktionell ist, und ein Maus-Adam6b-Protein oder ein Ortholog oder Homolog oder Fragment davon kodiert, das in einer männlichen Maus funktionell ist; und b) ein humanisierter Locus der variablen Region der schweren Immunglobulin-Kette.
DE14154918.8T 2011-02-25 2012-02-24 ADAM6 Mäuse Pending DE14154918T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161446895P 2011-02-25 2011-02-25
US201161446895P 2011-02-25
US201161497650P 2011-06-16 2011-06-16
US201161497650P 2011-06-16
US201261595200P 2012-02-06 2012-02-06
US201261595200P 2012-02-06
EP14154918.8A EP2738258B2 (de) 2011-02-25 2012-02-24 ADAM6 Mäuse

Publications (1)

Publication Number Publication Date
DE14154918T1 true DE14154918T1 (de) 2014-08-21

Family

ID=45998616

Family Applications (5)

Application Number Title Priority Date Filing Date
DE14154967.5T Pending DE14154967T1 (de) 2011-02-25 2012-02-24 ADAM6 Mäuse
DE14154918.8T Pending DE14154918T1 (de) 2011-02-25 2012-02-24 ADAM6 Mäuse
DE14176593.3T Pending DE14176593T1 (de) 2011-02-25 2012-02-24 ADAM6 Mäuse
DE12716101T Pending DE12716101T1 (de) 2011-02-25 2012-02-24 Adam6-mäuse
DE12192727T Pending DE12192727T1 (de) 2011-02-25 2012-02-24 ADAM6 Mäuse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE14154967.5T Pending DE14154967T1 (de) 2011-02-25 2012-02-24 ADAM6 Mäuse

Family Applications After (3)

Application Number Title Priority Date Filing Date
DE14176593.3T Pending DE14176593T1 (de) 2011-02-25 2012-02-24 ADAM6 Mäuse
DE12716101T Pending DE12716101T1 (de) 2011-02-25 2012-02-24 Adam6-mäuse
DE12192727T Pending DE12192727T1 (de) 2011-02-25 2012-02-24 ADAM6 Mäuse

Country Status (32)

Country Link
US (11) US8642835B2 (de)
EP (7) EP4067496B1 (de)
JP (7) JP2014507137A (de)
KR (1) KR101387377B1 (de)
CN (2) CN103429746B (de)
AU (5) AU2012243291B2 (de)
BR (1) BR112013021771B1 (de)
CA (1) CA2820824A1 (de)
CY (5) CY1116301T1 (de)
DE (5) DE14154967T1 (de)
DK (6) DK2578688T4 (de)
ES (6) ES2532487T3 (de)
FI (3) FI2578688T4 (de)
HK (2) HK1201292A1 (de)
HR (5) HRP20230526T1 (de)
HU (5) HUE046746T2 (de)
IL (4) IL226727A (de)
IN (1) IN2013CN07629A (de)
LT (4) LT2738259T (de)
ME (3) ME02106B (de)
MX (2) MX343009B (de)
MY (1) MY172713A (de)
NZ (2) NZ731926A (de)
PL (5) PL2738258T5 (de)
PT (5) PT2738259T (de)
RS (5) RS59661B2 (de)
RU (2) RU2722373C2 (de)
SG (4) SG10201913155QA (de)
SI (5) SI2738259T1 (de)
SM (1) SMT201500061B (de)
WO (1) WO2012141798A1 (de)
ZA (1) ZA201305998B (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009618A2 (en) 2002-07-18 2004-01-29 Crucell Holland B.V. Recombinant production of mixtures of antibodies
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
KR101457753B1 (ko) 2004-07-22 2014-11-03 에라스무스 유니버시티 메디컬 센터 로테르담 결합 분자
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20120204278A1 (en) * 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
EP3028565B1 (de) 2009-07-08 2017-09-27 Kymab Limited Tiermodelle und therapeutische moleküle
ES2728942T3 (es) 2010-02-08 2019-10-29 Regeneron Pharma Cadena ligera común de ratón
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
EP2601298B1 (de) 2010-08-02 2016-11-30 Regeneron Pharmaceuticals, Inc. Maüse, die vl domäne enthaltende bindende proteine machen
PL2738258T5 (pl) 2011-02-25 2023-05-15 Regeneron Pharmaceuticals, Inc. Myszy adam6
US10040826B2 (en) 2011-07-05 2018-08-07 Duke University Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens
SG10201914002RA (en) 2011-08-05 2020-03-30 Regeneron Pharma Humanized universal light chain mice
JP2014531452A (ja) 2011-09-19 2014-11-27 カイマブ・リミテッド 動物、レパートリーおよび方法
CA2846319A1 (en) 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
EP2761008A1 (de) 2011-09-26 2014-08-06 Kymab Limited Chimäre surrogatleichtketten (slc) mit humanem vpreb
WO2013052095A2 (en) 2011-10-03 2013-04-11 Duke University Vaccine
CN108200885B (zh) 2011-10-17 2021-12-14 瑞泽恩制药公司 受限制的免疫球蛋白重链基因座
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
AU2012323987B2 (en) * 2011-12-20 2015-07-09 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
RU2664185C2 (ru) * 2012-02-01 2018-08-15 Регенерон Фармасьютикалз, Инк. Гуманизированные грызуны, которые экспрессируют тяжелые цепи, содержащие домены vl
RS59076B1 (sr) 2012-03-16 2019-09-30 Regeneron Pharma Glodari koji eksprimiraju imunoglobulinske sekvence senzitivne na ph
NZ629639A (en) 2012-03-16 2017-03-31 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
SG10201607727PA (en) 2012-03-16 2016-11-29 Regeneron Pharma Mice that produce antigen-binding proteins with ph-dependent binding characteristics
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
KR20230091201A (ko) 2012-04-20 2023-06-22 메뤼스 엔.페. Ig-유사 분자의 제조방법 및 제조수단
LT2858487T (lt) * 2012-06-12 2019-12-27 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, kurie yra humanizuoti ir turi redukuotą imunoglobulino sunkiosios grandinės lokusą
US9963501B2 (en) 2013-02-06 2018-05-08 Regeneron Pharmaceuticals, Inc. B cell lineage based immunogen design with humanized animals
AU2014218915B2 (en) 2013-02-20 2017-01-19 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
EP2967012B1 (de) * 2013-03-14 2020-09-16 Erasmus University Medical Center Rotterdam Transgenes nicht-menschliches säugetier für die produktion von antikörpern
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
JP6267986B2 (ja) * 2014-02-13 2018-01-24 株式会社特殊免疫研究所 ヒトの特定分子と結合する分子標的物質のｉｎｖｉｖｏ評価法
JP2017510273A (ja) 2014-03-21 2017-04-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 異なる結合特性を示すｖｌ抗原結合タンパク質
KR102601491B1 (ko) 2014-03-21 2023-11-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
EP3193592A1 (de) 2014-09-19 2017-07-26 Regeneron Pharmaceuticals, Inc. Chimäre antigenrezeptoren
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
IL302725A (en) 2016-01-13 2023-07-01 Regeneron Pharma Rodents with an engineered DIVERSITY region of the heavy chain
WO2017143062A1 (en) 2016-02-16 2017-08-24 Regeneron Pharmaceuticals, Inc. Non-human animals having a mutant kynureninase gene
KR102356542B1 (ko) * 2016-05-20 2022-01-28 리제너론 파마슈티칼스 인코포레이티드 다중 가이드 RNAs를 이용한 면역학적 내성 파괴 방법
IL263160B2 (en) 2016-06-03 2024-01-01 Regeneron Pharma Non-human animals expressing exogenous terminal deoxynucleotidyl transferase
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
CN109996441B (zh) 2016-11-04 2022-02-08 瑞泽恩制药公司 具有经工程化的免疫球蛋白λ轻链基因座的非人类动物
US11122042B1 (en) 2017-05-12 2021-09-14 F5 Networks, Inc. Methods for dynamically managing user access control and devices thereof
MA50546A (fr) 2017-06-07 2020-09-16 Regeneron Pharma Compositions et méthodes pour l'internalisation d'enzymes
US11051498B2 (en) 2017-12-05 2021-07-06 Regeneron Pharmaceuticals, Inc. Mouse having an engineered immunoglobulin lambda light chain
BR112020019026A2 (pt) 2018-03-24 2020-12-29 Regeneron Pharmaceuticals, Inc. Animal não humano geneticamente modificado, métodos para produzir o animal não humano geneticamente modificado, para geração de uma proteína de ligação a antígeno, para obtenção de um ácido nucleico, e, para obtenção de uma célula que expressa um domínio variável de cadeia pesada de imunoglobulina humana e/ou um domínio variável de cadeia leve de imunoglobulina humana, método in vitro de produção de um domínio variável de imunoglobulina humana, ácido nucleico, célula hospedeira, célula isolada, e, domínio variável de cadeia pesada de imunoglobulina humana
CN116420679A (zh) 2018-03-26 2023-07-14 瑞泽恩制药公司 用于测试治疗剂的人源化啮齿动物
US20210079109A1 (en) 2018-05-17 2021-03-18 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
WO2019240999A1 (en) * 2018-06-13 2019-12-19 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
LT3629720T (lt) 2018-06-14 2022-03-10 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, gebantys vykdyti imunoglobulino sunkiosios grandinės koduojančių sekų dh-dh pertvarkymą
CA3125380A1 (en) 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
CN113473850A (zh) 2019-02-22 2021-10-01 瑞泽恩制药公司 具有遗传修饰的钠通道的啮齿动物及其使用方法
CA3136478A1 (en) 2019-06-05 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
EP3785536B1 (de) * 2019-08-28 2022-01-26 Trianni, Inc. Adam6-knockin-mäuse
CN114901678A (zh) 2019-12-02 2022-08-12 瑞泽恩制药公司 肽-mhc ii蛋白构建体及其用途
IL301137A (en) 2020-09-11 2023-05-01 Regeneron Pharma Identification and production of antigen-specific antibodies
IL303626A (en) 2020-12-16 2023-08-01 Regeneron Pharma Mice expressing human FC alpha receptors
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
KR20230124594A (ko) 2020-12-23 2023-08-25 리제너론 파마슈티칼스 인코포레이티드 막관통 단백질 및 이를 생산하는 세포에 결합하는 항체를 수득하는 방법
WO2022225985A1 (en) 2021-04-20 2022-10-27 Regeneron Pharmaceuticals, Inc. Human antibodies to artemin and methods of use thereof
WO2024015816A1 (en) 2022-07-12 2024-01-18 Regeneron Pharmaceuticals, Inc. Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0671951A4 (de) * 1992-12-01 1997-05-21 Protein Design Labs Inc Humanisierte antikörper, die mit 1-selektine reagieren.
EP2305027B1 (de) * 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgene Saügertiere, die menschlichen Ig-loci einschließlich mehrere VH und Vkappa Regionen enthalten, und davon erhaltene Antikörper
CN1203922A (zh) * 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
RU10506U1 (ru) 1999-04-08 1999-08-16 Кривулин Виталий Николаевич Ручной культиватор
WO2004009618A2 (en) 2002-07-18 2004-01-29 Crucell Holland B.V. Recombinant production of mixtures of antibodies
WO2000073323A2 (en) * 1999-05-27 2000-12-07 Human Genome Sciences, Inc. Adam polynucleotides and polypeptides
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
ATE398172T1 (de) * 2001-05-11 2008-07-15 Kirin Pharma Kk Künstliches menschliches chromosom mit dem gen für die lambda-leichte kette menschlicher antikörper
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
US20030108925A1 (en) 2001-10-05 2003-06-12 U.S. Epa Genetic testing for male factor infertility
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
JP4099646B2 (ja) 2002-06-04 2008-06-11 株式会社安川電機 ボイスコイルモータ
RU2251699C1 (ru) 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
DK1802193T3 (da) 2004-10-19 2014-06-10 Regeneron Pharma Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation
ES2318384T3 (es) 2005-06-30 2009-05-01 Borealis Technology Oy Capa exterior de funda para cables de potencia o de comuniccion.
US7910798B2 (en) 2006-03-31 2011-03-22 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
PT2374818E (pt) 2006-06-02 2013-02-13 Regeneron Pharma Anticorpos com elevada afinidade para o receptor il-6 humano
EP2185692A4 (de) 2007-08-10 2012-05-02 Medarex Inc Hco32 und hco27 sowie entsprechende beispiele
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
AU2009298458B2 (en) 2008-09-30 2015-10-08 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
RU2011129459A (ru) * 2008-12-18 2013-01-27 Эрасмус Юниверсити Медикал Сентр Роттердам Трансгенные животные (не человек), экспрессирующие гуманизированные антитела, и их применение
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
JP5399140B2 (ja) * 2009-06-18 2014-01-29 株式会社タイトー モールス信号通信システム
EP3028565B1 (de) * 2009-07-08 2017-09-27 Kymab Limited Tiermodelle und therapeutische moleküle
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
SG181477A1 (en) 2009-12-10 2012-07-30 Regeneron Pharma Mice that make heavy chain antibodies
ES2728942T3 (es) 2010-02-08 2019-10-29 Regeneron Pharma Cadena ligera común de ratón
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
EP2582230A1 (de) * 2010-06-17 2013-04-24 Kymab Limited Tiermodelle und therapeutische moleküle
PL2738258T5 (pl) 2011-02-25 2023-05-15 Regeneron Pharmaceuticals, Inc. Myszy adam6
SG10201914002RA (en) 2011-08-05 2020-03-30 Regeneron Pharma Humanized universal light chain mice
CN108200885B (zh) 2011-10-17 2021-12-14 瑞泽恩制药公司 受限制的免疫球蛋白重链基因座
GB201118579D0 (en) 2011-10-27 2011-12-07 Micromass Ltd Control of ion populations
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
AU2012323987B2 (en) 2011-12-20 2015-07-09 Regeneron Pharmaceuticals, Inc. Humanized light chain mice

Also Published As

Publication number Publication date
SG10201405135RA (en) 2014-10-30
ES2770424T3 (es) 2020-07-01
AU2020201279A1 (en) 2020-03-12
EP2578688B2 (de) 2023-02-08
US20210105985A1 (en) 2021-04-15
FI2738258T4 (fi) 2023-05-05
ES2532487T3 (es) 2015-03-27
SI2738258T2 (sl) 2023-05-31
NZ703609A (en) 2016-04-29
ES2805364T3 (es) 2021-02-11
NZ776770A (en) 2023-03-31
DK2738258T3 (da) 2019-12-16
DE14154967T1 (de) 2014-08-28
EP2813573A1 (de) 2014-12-17
DK2738259T3 (da) 2020-02-17
DK4067496T3 (da) 2023-06-26
CA2820824A1 (en) 2012-10-18
RS59661B2 (sr) 2023-06-30
RU2582261C2 (ru) 2016-04-20
ME02106B (me) 2015-10-20
RS64280B1 (sr) 2023-07-31
DK2738259T1 (da) 2014-11-24
NZ612643A (en) 2015-06-26
US20180345760A1 (en) 2018-12-06
PL2738258T5 (pl) 2023-05-15
SI2550363T1 (sl) 2015-04-30
DK2738258T4 (da) 2023-05-08
ES2748832T5 (es) 2023-06-08
PL4067496T3 (pl) 2023-07-31
DK2578688T3 (da) 2019-10-28
EP2738258B1 (de) 2019-09-25
WO2012141798A1 (en) 2012-10-18
RS59661B1 (sr) 2020-01-31
EP2738258A2 (de) 2014-06-04
US20180346598A1 (en) 2018-12-06
SMT201500061B (it) 2015-05-05
LT2578688T (lt) 2019-11-11
CY1122820T1 (el) 2021-05-05
FI4067496T3 (fi) 2023-05-24
KR101387377B1 (ko) 2014-04-21
LT2738258T (lt) 2020-01-10
CN103429746A (zh) 2013-12-04
EP2738259A3 (de) 2014-07-30
JP5866127B2 (ja) 2016-02-17
LT2738259T (lt) 2020-03-10
HRP20150262T1 (hr) 2015-04-10
EP2738259B1 (de) 2019-11-27
HK1174490A1 (en) 2013-06-14
PL2550363T3 (pl) 2015-05-29
RS53880B1 (en) 2015-08-31
AU2022206806A1 (en) 2022-08-18
SG10201913160QA (en) 2020-03-30
MX2013009649A (es) 2013-09-26
JP2019187446A (ja) 2019-10-31
MY172713A (en) 2019-12-11
ES2758974T5 (es) 2023-06-08
EP3744850A1 (de) 2020-12-02
NZ718688A (en) 2017-07-28
EP2738258B2 (de) 2023-02-01
RU2013125717A (ru) 2014-12-10
CN105861548B (zh) 2020-01-10
EP2578688B1 (de) 2019-07-24
IN2013CN07629A (de) 2015-08-07
DK2813573T1 (da) 2015-01-12
RS59413B1 (sr) 2019-11-29
EP4067496A1 (de) 2022-10-05
JP2015107131A (ja) 2015-06-11
US20180346599A1 (en) 2018-12-06
JP2014110814A (ja) 2014-06-19
US20140213773A1 (en) 2014-07-31
JP2016135143A (ja) 2016-07-28
SI4067496T1 (sl) 2023-07-31
IL273986B (en) 2021-04-29
IL226727A (en) 2016-08-31
PT2738259T (pt) 2020-02-18
EP2738258A3 (de) 2014-09-24
US10577430B2 (en) 2020-03-03
EP2550363B1 (de) 2014-12-10
ME03732B (de) 2021-01-20
PL2738258T3 (pl) 2020-08-24
IL273986A (en) 2020-05-31
US20210105984A1 (en) 2021-04-15
US8697940B2 (en) 2014-04-15
PT2578688T (pt) 2019-10-24
US11950578B2 (en) 2024-04-09
NZ731926A (en) 2021-07-30
RU2722373C2 (ru) 2020-05-29
CN105861548A (zh) 2016-08-17
PT4067496T (pt) 2023-06-07
BR112013021771B1 (pt) 2022-11-16
DE12192727T1 (de) 2013-07-11
EP2550363A1 (de) 2013-01-30
AU2017251802A1 (en) 2017-11-16
JP2022071051A (ja) 2022-05-13
MX2020009714A (es) 2020-10-07
HRP20200294T1 (hr) 2020-05-29
SG192933A1 (en) 2013-09-30
JP2018143250A (ja) 2018-09-20
AU2012243291A1 (en) 2013-05-09
US9944716B2 (en) 2018-04-17
EP2578688A1 (de) 2013-04-10
US9932408B2 (en) 2018-04-03
SI2738258T1 (sl) 2020-01-31
DK2550363T3 (en) 2015-03-23
US8642835B2 (en) 2014-02-04
RS59929B1 (sr) 2020-03-31
DE12716101T1 (de) 2013-05-08
HK1201292A1 (en) 2015-08-28
CN103429746B (zh) 2016-05-11
AU2012243291B2 (en) 2015-07-09
ES2748832T3 (es) 2020-03-18
DK2738258T1 (da) 2014-11-24
JP2014507137A (ja) 2014-03-27
HUE062552T2 (hu) 2023-11-28
BR112013021771A2 (pt) 2017-07-04
PT2550363E (pt) 2015-03-16
AU2015238806A1 (en) 2015-10-29
PL2578688T3 (pl) 2020-05-18
EP2738259A2 (de) 2014-06-04
US10905109B2 (en) 2021-02-02
PL2578688T5 (pl) 2023-05-29
US10694725B2 (en) 2020-06-30
IL261243B (en) 2019-08-29
ME03537B (de) 2020-04-20
CY1122459T1 (el) 2021-01-27
US20150201589A1 (en) 2015-07-23
ES2758974T3 (es) 2020-05-07
HUE046081T2 (hu) 2020-01-28
US20130254911A1 (en) 2013-09-26
US20120322108A1 (en) 2012-12-20
IL268671B (en) 2020-05-31
EP2813573B1 (de) 2020-04-22
HUE047687T2 (hu) 2020-05-28
IL261243A (en) 2018-10-31
IL268671A (en) 2019-10-31
RS59413B2 (sr) 2023-06-30
RU2016109443A3 (de) 2019-07-24
HUE024534T2 (hu) 2016-01-28
SI2578688T2 (sl) 2023-05-31
HUE046746T2 (hu) 2020-03-30
CY1122205T1 (el) 2020-11-25
HRP20230526T1 (hr) 2023-09-01
ZA201305998B (en) 2016-07-27
HRP20192311T1 (hr) 2020-03-20
US20150210776A1 (en) 2015-07-30
ES2946169T3 (es) 2023-07-13
FI2578688T4 (fi) 2023-05-05
RU2016109443A (ru) 2018-11-26
KR20130116375A (ko) 2013-10-23
US20180362663A1 (en) 2018-12-20
DE14176593T1 (de) 2015-03-05
EP4067496B1 (de) 2023-03-29
US10905108B2 (en) 2021-02-02
HRP20192311T4 (hr) 2023-05-12
CY1126091T1 (el) 2023-11-15
HRP20191895T1 (hr) 2020-01-10
PL2738259T3 (pl) 2020-08-24
HRP20191895T4 (hr) 2023-05-12
US10072095B2 (en) 2018-09-11
DK2578688T4 (da) 2023-05-08
LT4067496T (lt) 2023-06-12
MX343009B (es) 2016-10-21
PT2738258T (pt) 2019-12-10
SI2738259T1 (sl) 2020-06-30
CY1116301T1 (el) 2017-02-08
SI2578688T1 (sl) 2019-11-29
DK2578688T1 (da) 2014-11-24
SG10201913155QA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
DE14154918T1 (de) ADAM6 Mäuse
HRP20192218T1 (hr) Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene
HRP20200093T1 (hr) Humanizirane neljudske životinje s ograničenim lokusima imunoglobulinskog teškog lanca
CN104302171B (zh) 表达ph敏感性免疫球蛋白序列的非人动物
RU2014108208A (ru) Мыши с гуманизированной универсальной легкой цепью
HRP20201403T1 (hr) Neljudske životinje koje imaju genetski modificiran lokus imunoglobulinskog lambda lakog lanca
HRP20191680T1 (hr) Neljudske životinje koje izražavaju antitijela sa zajedničkim lakim lancem
HRP20210662T1 (hr) Neljudske životinje koje imaju humanizirani gen za diferencijacijski biljeg 47
HRP20171357T1 (hr) Ograničeni teški lanac imunoglobulina u miševa
JP2016127840A5 (de)
SI3027015T1 (en) HUMANIZED IL-4 AND IL-4R ALPHA ANIMALS
RU2014127339A (ru) Мыши с гуманизированной легкой цепью
ES2738679T3 (es) Anticuerpos de cadena ligera diseñados genéticamente con histidina y animales no humanos modificados genéticamente para generar los mismos
HRP20201259T1 (hr) Protutijela protiv ox40 i njihova upotreba
BR112015019350A2 (pt) Animal não humano, locus de imunoglobulina, e, métodos de fabricação de um animal não humano, para a obtenção de uma sequência de ácido nucleico e de fabricação de uma proteína de ligação ao antígeno
JP2014110814A5 (de)
JP2015505477A5 (de)
RU2014141537A (ru) Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения
JP2014524243A5 (de)
JP2015510769A5 (de)
RU2016141123A (ru) Антигенсвязывающие белки vl, проявляющие различные связывающие характеристики
RU2017134418A (ru) Выявление аффинно-зрелых человеческих антител
JP2015501146A5 (de)
RU2022109215A (ru) Гуманизированные грызуны, которые экспрессируют тяжелые цепи, содержащие домены vl
Vernersson et al. Cloning and structural analysis of two highly divergent IgA isotypes, IgA1 and IgA2 from the duck billed platypus, Ornithorhynchus anatinus